Form 8-K · Current Report · Filed 2025-01-13
Apellis Pharmaceuticals Announces Preliminary 2024 Revenues and Key Executive Changes
Apellis Pharmaceuticals, Inc. announced preliminary unaudited U.S. net product revenues for 2024, with SYFOVRE contributing $611 million and EMPAVELI contributing $98 million. The company also reported a strong financial position with year-end cash of approximately $410 million. Additionally, the company announced the departure of Chief Operating Officer Adam Townsend and the appointment of Keli Walbert to the Board of Directors.
- Filer
- Apellis Pharmaceuticals Inc. APLS · NASDAQ
- Filed
- Accession
- 0001193125-25-005052
- CIK
- 0001492422
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Financial Statements and Exhibits
Market reaction
Close before filing
$4.95
Next session
-0.1%
Since filing
-31.3%
Latest close
$3.40
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from APLS reporting the same item, with the next session's move:
Exhibits (1)
About Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapeutic compounds to address complement-mediated diseases. The primary focus of Apellis is to pioneer medicines leveraging targeted inhibition of the complement system, a key component of the immune system that plays a crucial role in a variety of diseases. The company's flagship product, targeting diseases such as geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH), highlights its commitment to addressing unmet medical needs with innovative treatments. Apellis Pharmaceuticals operates in the highly competitive pharmaceutical and biotechnology industry, collaborating with healthcare providers and research institutions to advance clinical treatment options. Headquartered in Waltham, Massachusetts, its contributions to medical science are significant, paving the way for advancements in immunology and therapy development. As a publicly traded entity, Apellis influences the healthcare sector by enhancing treatment paradigms and offering new hope for patients with chronic and debilitating conditions.
Never miss another APLS filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.